Cover Image
市場調查報告書

PharmaPoint:大腸躁鬱症 (IBS) - 現在·未來的主要企業

PharmaPoint: Irritable Bowel Syndrome - Current and Future Players

出版商 GlobalData 商品編碼 325953
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:大腸躁鬱症 (IBS) - 現在·未來的主要企業 PharmaPoint: Irritable Bowel Syndrome - Current and Future Players
出版日期: 2014年12月31日 內容資訊: 英文 54 Pages
簡介

本報告提供全球大腸躁鬱症 (IBS) 的治療藥市場相關調查分析,以構成市場的主要企業 (新加入企業) 為焦點,提供您競爭情形相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素與阻礙

第4章 現在·未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Actavis
    • Astellas
    • Almirall
    • Ironwood
    • 武田藥品工業
    • Sucampo
    • Prometheus
    • Salix
    • Menarini
    • Synergy
    • AstraZeneca

第5章 附錄

圖表

目錄
Product Code: GDHC1042FPR

GlobalData has released its pharma report, "PharmaPoint: Irritable Bowel Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Irritable Bowel Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Irritable Bowel Syndrome market. The report provides insight into the competitive Irritable Bowel Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Irritable Bowel Syndrome
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Irritable Bowel Syndrome sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Irritable Bowel Syndrome market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Irritable Bowel Syndrome market landscape? Identify, understand and capitalize

Table of Contents

1 . Table of Contents

  • 1.1 . List of Tables
  • 1.2 . List of Figures

2 . Introduction

  • 2.1 . Catalyst
  • 2.2 . Related Reports

3 . Market Outlook

  • 3.1 . Global Markets
    • 3.1.1 . Forecast
    • 3.1.2 . Drivers and Barriers - Global Issues

4 . Current and Future Players

  • 4.1 . Overview
  • 4.2 . Trends in Corporate Strategy
  • 4.3 . Company Profiles
    • 4.3.1 . Actavis
    • 4.3.2 . Astellas
    • 4.3.3 . Almirall
    • 4.3.4 . Ironwood
    • 4.3.5 . Takeda
    • 4.3.6 . Sucampo
    • 4.3.7 . Prometheus
    • 4.3.8 . Salix
    • 4.3.9 . Menarini
    • 4.3.10 . Synergy
    • 4.3.11 . AstraZeneca

5 . Appendix

  • 5.1 . Bibliography
  • 5.2 . Abbreviations
  • 5.3 . Methodology
  • 5.4 . Forecasting Methodology
    • 5.4.1 . Diagnosed IBS Patients
    • 5.4.2 . General Pricing Assumptions
    • 5.4.3 . Generic Erosion
  • 5.5 . Primary Research - KOLs Interviewed for This Report
  • 5.6 . About the Authors
    • 5.6.1 . Analyst
    • 5.6.2 . Therapy Area Director
    • 5.6.3 . Global Head of Healthcare
  • 5.7 . About GlobalData
  • 5.8 . Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for IBS, 2013-2023
  • Table 2: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the IBS Market in the 7MM, 2014
  • Table 4: Actavis' IBS Portfolio Assessment, 2014
  • Table 5: Astellas' IBS Portfolio Assessment, 2014
  • Table 6: Almirall's IBS Portfolio Assessment, 2014
  • Table 7: Ironwood's IBS Portfolio Assessment, 2014
  • Table 8: Takeda's IBS Portfolio Assessment, 2014
  • Table 9: Sucampo's IBS Portfolio Assessment, 2014
  • Table 10: Prometheus' IBS Portfolio Assessment, 2014
  • Table 11: Salix's IBS Portfolio Assessment, 2014
  • Table 12: Menarini's IBS Portfolio Assessment, 2014
  • Table 13: Synergy's IBS Portfolio Assessment, 2014
  • Table 14: AstraZeneca's IBS Portfolio Assessment, 2014

List of Figures

  • Figure 1: Global Sales for IBS by Region, 2013-2023
  • Figure 2: Company Portfolio Gap Analysis in IBS, 2013-2023
  • Figure 3: Actavis' SWOT Analysis in IBS, 2013-2023
  • Figure 4: Astellas' SWOT Analysis in IBS, 2013-2023
  • Figure 5: Almirall's SWOT Analysis in IBS, 2013-2023
  • Figure 6: Ironwood's SWOT Analysis in IBS, 2013-2023
  • Figure 7: Takeda's SWOT Analysis in IBS, 2013-2023
  • Figure 8: Sucampo's SWOT Analysis in IBS, 2013-2023
  • Figure 9: Prometheus' SWOT Analysis in IBS, 2013-2023
  • Figure 10: Salix's SWOT Analysis in IBS, 2013-2023
  • Figure 11: Menarini's SWOT Analysis in IBS, 2013-2023
  • Figure 12: Synergy's SWOT Analysis in IBS, 2013-2023
  • Figure 13: AstraZeneca's SWOT Analysis in IBS, 2013-2023
Back to Top